Form D · Biotechnology

Galvanize Therapeutics, Inc.

Redwood City, CA · CIK 0001659073

Offering snapshot reported Sep 11, 2025 · SEC filing

Reported sold
$96.1M
Offering amount: $141M
Investors reported
28
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Jul 7, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 11, 2025Initial$96,130,465No comparison28SEC filing
Mar 22, 2022Initial$4,000,000No comparison1SEC filing
Mar 9, 2022Initial$2,000,000No comparison1SEC filing
Nov 18, 2019Amendment$42,514,946$15,000,000vs Mar 13, 20191SEC filing
Mar 13, 2019Initial$27,514,946No comparison1SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
$0
Finders' fees
$0
Form D file number
021-557260
For the total amount sold: $60,467,996.83 new money; $35,662,468.47 conversion of debt

Source: Form D, filed Sep 11, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steve Anheier Executive
Doug Godshall Director, Executive
Seth Harrison Director
David Lewis Director
David Mc Intyre Director
Antoine Papiernik Director
Zack Scott Director
Jonathan Waldstreicher Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3200 Bridge Parkway
Redwood City, CA, 94065